Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

nhibitors; and the enabling capabilities of Cytokinetics biological focus. Such statements are based on management s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, that GSK or the NCI may decide to postpone or discontinue development efforts for GSK-923295 or ispinesib, respectively; that there may be difficulties or delays potential difficulties or delays in the development, testing, regulatory approval, production and marketing of Cytokinetics drug candidates that could slow or prevent clinical development, product approval or market acceptance, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy, and Cytokinetics may not be able to obtain and maintain patent or trade secret protection for its intellectual property; that Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing if necessary; and that standards of care may change or others may introduce products or alternative therapies for the treatment of indications which Cytokinetics drug candidates and potential drug candidates currently or potentially target. For further information regarding these and other risks related to Cytokinetics business, investors should consult Cytokinetics filings with the Securities and Exchange Commission.


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... DIEGO, March 10 Avineuro Pharmaceuticals, Inc. announced today ... a potent and selective small molecule antagonist of 5-HT6 ... I studies are expected to be available in April ... Inc. plans to advance AVN-211 into Phase II clinical ...
... March 9 What if after 100 years of ... conquest of cancer, a small, unheralded, non-profit organization could ... , , Improbable? Perhaps. Impossible? ... garage revolutionized the computer industry? , , ...
Cached Medicine Technology:Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 2Cancer Research 'David' Hopes to Slay 'Cancer Goliath' 3
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value ... US, France, Italy, Germany, Spain and the UK), from ... , The competitive landscape in the B-cell NHL markets ... UK is poised to undergo a dramatic shift during ... B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma ...
(Date:9/1/2014)... Monday 1 September 2014: Daily fruit consumption cuts ... 40%, according to research presented at ESC Congress today ... from the seven year follow-up study of nearly 0.5 ... the more fruit people ate, the more their risk ... ischaemic heart disease (IHD) and stroke, is the leading ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... Get Discount to Switch , ... ... provider of Internet practice management and www.CollaborateMD.com [medical ... program for existing users of Medisoft, Lytec, AltaPoint, Medical Manager ...
... supporters join call for fair & enforceable union,election ground ... is being issued by SEIU United Healthcare Workers - ... System and their supporters,presented an open letter to the ... women religious to help stop the unlawful threats and,intimidation ...
... Minn., Aug. 13 The CHS Foundation,announced today ... the Ralph K.,Morris Foundation,s new Elroy Webster Cooperative ... honorary award to graduate and law,students interested in ... created in memory of Elroy Webster, a,Minnesota farmer ...
... STEN ), a Minneapolis-based diversified business, today reported,results ... June 29,2008. The Company reported a net after-tax ... the third quarter period ended June 29, 2008. ... were $5,035,913, an,increase of 377 percent, or $3,979,309 ...
... cancer,research/programs, DETROIT, Aug. 13 Sean Shearon wanted ... cancer, as well as honor the victims,and survivors of ... 18,marathons in 18 days -- The Victory Walk -- ... programs at the Barbara Ann Karmanos Cancer,Institute, in Detroit. ...
... (August 13, 2008) SAGE, the world,s fifth largest journals ... agreement to publish the Journal of Dental Research ... publication of the International and American Associations for Dental Research ... dedicated to the dissemination of new knowledge and information on ...
Cached Medicine News:Health News:CollaborateMD Offers Upgrade Program to Competitors' Users 2Health News:As Charges Mount, Caregivers and Supporters Call on Sisters of St. Joseph of Orange to Help Stop Unlawful Intimidation of Workers 2Health News:CHS Foundation Helps Launch New Scholarship Fund 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 3Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 4Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 5Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:SAGE to publish Journal of Dental Research beginning in 2009 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: